Igarashi Masayuki, Ishizaki Yoshimasa, Takahashi Yoshiaki
Institute of Microbial Chemistry (BIKAKEN), Tokyo, Japan.
J Antibiot (Tokyo). 2017 Nov 1. doi: 10.1038/ja.2017.126.
Tuberculosis is one of the most common and challenging infectious diseases worldwide. Especially, the lack of effective chemotherapeutic drugs for tuberculosis/human immunodeficiency virus co-infection and prevalence of multidrug-resistant and extensively drug-resistant tuberculosis remain to be serious clinical problems. Development of new drugs is a potential solution to fight tuberculosis. In this decade, the development status of new antituberculous drugs has been greatly advanced by the leading role of international organizations such as the Global Alliance for Tuberculosis Drug Development, Stop Tuberculosis Partnership and Global Health Innovative Technology Fund. In this review, we introduce the development status of new drugs for tuberculosis, focusing on those derived from natural products.The Journal of Antibiotics advance online publication, 1 November 2017; doi:10.1038/ja.2017.126.
结核病是全球最常见且极具挑战性的传染病之一。特别是,缺乏针对结核病/人类免疫缺陷病毒合并感染的有效化疗药物,以及耐多药和广泛耐药结核病的流行,仍然是严重的临床问题。开发新药是对抗结核病的一个潜在解决方案。在这十年中,全球结核病药物研发联盟、终止结核病伙伴关系和全球卫生创新技术基金等国际组织发挥主导作用,极大地推动了新型抗结核药物的研发进展。在本综述中,我们介绍了抗结核新药的研发状况,重点关注源自天然产物的药物。《抗生素杂志》于2017年11月1日在线优先发表;doi:10.1038/ja.2017.126 。